Novartis lifts profit outlook as new medicines counter generic erosion
TBE/iStock Editorial via Getty Images
Novartis AG (NVS) improved its full-year profit outlook on Tuesday after stronger demand for newer medicines helped offset generic competition for its blockbuster heart drug Entresto.
The Swiss drugmaker now expects full-year core operating income to remain broadly in line
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.